GliaCure Completes Phase 1a Clinical Trial in Alzheimer's Disease
BOSTON, Jan. 6, 2015 /PRNewswire-USNewswire/ -- GliaCure, a privately-held biotechnology company focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glial targets, announced today that it has successfully completed its Phase 1a clinical trial of its lead product candidate, GC021109, a compound developed as a disease-modifying treatment for Alzheimer's disease. The trial, which began on September 22, 2014, included single dosing of 44 healthy volunteers and demonstrated the safety, tolerability, and excellent pharmacokinetic properties of GC021109.
"We are very excited to have reached yet another milestone in the development of GC021109," said GliaCure director and co-founder Mike Szulczewski. "We look forward to testing the safety and tolerability of the drug in mild to moderate Alzheimer's patients, and of course to ultimately producing a therapy that can modify the disease, at least in its early stages, rather than just treat symptoms." GliaCure's approach to treating Alzheimer's disease is novel in that it promotes both the clearance of amyloid and stimulates anti-inflammatory actions through a single target.
Data from GliaCure's Phase 1a study is being used to determine dosing in the company's upcoming Phase 1b trial, a multiple ascending dose study in mild-to-moderate Alzheimer's patients. Site selection for this Phase 1b trial is currently underway and first dosing is planned for Q1 2015.
About GliaCure, Inc.
GliaCure is a privately held company that is pioneering the development of novel therapeutics aimed at treating neurological and neuropsychiatric disorders of the brain. The company's approaches are based on glial targets, a cell type in the brain that has previously been largely overlooked in drug discovery. GliaCure's lead product candidate, GC021109, is a small molecule that in preclinical studies has demonstrated two primary actions downstream of target engagement: the stimulation of phagocytosis and anti-inflammatory actions in which levels of pro-inflammatory cytokines are reduced. GC021109 is currently being developed primarily as a disease modifying treatment for Alzheimer's disease and commenced a Phase 1a clinical trial for the disorder in Q3 2014. The dual phagocytic and anti-inflammatory actions of GC021109 have the potential to affect other disorders, including psoriasis, Parkinson's disease, and multiple sclerosis. GliaCure has an exclusive license to the GC021109 compound and related technology from Tufts University. GliaCure also has a pipeline program for the development of therapeutics for astrocytic targets related to sleep disorders and depression. The company is based in Boston and is led by Professor Philip G. Haydon, who also holds the position of Chair of Neuroscience at Tufts University.
CONTACT: Yolande Haydon, 610-246-6012, [email protected]
SOURCE GliaCure, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article